Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.
2.

Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.

Habuchi T, Liqing Z, Suzuki T, Sasaki R, Tsuchiya N, Tachiki H, Shimoda N, Satoh S, Sato K, Kakehi Y, Kamoto T, Ogawa O, Kato T.

Cancer Res. 2000 Oct 15;60(20):5710-3.

3.

Lack of association between CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis of 22,090 cases and 28,498 controls.

Mao C, Wang XW, He BF, Qiu LX, Liao RY, Luo RC, Chen Q.

Breast Cancer Res Treat. 2010 Jul;122(1):259-65. doi: 10.1007/s10549-009-0695-4. Epub 2009 Dec 24.

PMID:
20033766
4.

Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis.

Ntais C, Polycarpou A, Ioannidis JP.

Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):120-6. Review.

5.

CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study.

Verla-Tebit E, Wang-Gohrke S, Chang-Claude J.

Breast Cancer Res. 2005;7(4):R455-64. Epub 2005 Apr 12.

6.

The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis.

Ye Z, Parry JM.

Mutagenesis. 2002 Mar;17(2):119-26.

7.

CYP17 gene polymorphism and its association in north Indian prostate cancer patients.

Sobti RC, Gupta L, Thakur H, Seth A, Singh SK, Kaur P.

Anticancer Res. 2009 May;29(5):1659-63.

8.

A polymorphism in the CYP17 gene relates to the risk of recurrent pregnancy loss.

Sata F, Yamada H, Yamada A, Kato EH, Kataoka S, Saijo Y, Kondo T, Tamaki J, Minakami H, Kishi R.

Mol Hum Reprod. 2003 Nov;9(11):725-8.

9.

[Association between the polymorphism of CYP17 gene and risk of prostate cancer in chinese vigurs men].

Guli MR, Wang JQ, Zhang JX, Deng G.

Zhonghua Nan Ke Xue. 2006 Feb;12(2):120-2. Chinese.

PMID:
16519145
10.

A polymorphism in the CYP17 gene is associated with prostate cancer risk.

Gsur A, Bernhofer G, Hinteregger S, Haidinger G, Schatzl G, Madersbacher S, Marberger M, Vutuc C, Micksche M.

Int J Cancer. 2000 Aug 1;87(3):434-7.

11.

Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).

Lunn RM, Bell DA, Mohler JL, Taylor JA.

Carcinogenesis. 1999 Sep;20(9):1727-31.

12.

The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.

Haiman CA, Stampfer MJ, Giovannucci E, Ma J, Decalo NE, Kantoff PW, Hunter DJ.

Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):743-8.

13.

A polymorphism in the CYP17 gene and risk of prostate cancer.

Stanford JL, Noonan EA, Iwasaki L, Kolb S, Chadwick RB, Feng Z, Ostrander EA.

Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):243-7.

14.

The CYP17 MspA1 polymorphism is not associated with an increased risk of uterine leiomyomas in a Japanese population.

Tsujino T, Ohara N, Yoshida S, Kennedy S, Takemura N, Deguchi M, Maruo T.

Gynecol Endocrinol. 2006 Feb;22(2):87-91.

PMID:
16603433
15.

CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.

Madigan MP, Gao YT, Deng J, Pfeiffer RM, Chang BL, Zheng S, Meyers DA, Stanczyk FZ, Xu J, Hsing AW.

Int J Cancer. 2003 Nov 1;107(2):271-5. Review.

16.

No association between CYP17 T-34C polymorphism and breast cancer risk: a meta-analysis involving 58,814 subjects.

Yao L, Fang F, Wu Q, Yang Z, Zhong Y, Yu L.

Breast Cancer Res Treat. 2010 Jul;122(1):221-7. doi: 10.1007/s10549-009-0679-4. Epub 2009 Dec 15.

PMID:
20013047
17.

Role of a CYP17 promoter polymorphism for familial prostate cancer risk in Germany.

Vesovic Z, Herkommer K, Vogel W, Paiss T, Maier C.

Anticancer Res. 2005 Mar-Apr;25(2B):1303-7.

18.

CYP17 MspA1 polymorphism and risk of biliary tract cancers and gallstones: a population-based study in Shanghai, China.

Hou L, Xu J, Gao YT, Rashid A, Zheng SL, Sakoda LC, Shen MC, Wang BS, Deng J, Han TQ, Zhang BH, Meyers DA, Fraumeni JF Jr, Hsing AW.

Int J Cancer. 2006 Jun 1;118(11):2847-53.

19.

No association of the 5' promoter region polymorphism of CYP17 gene with prostate cancer risk.

dos Santos A, Ribeiro ML, Mesquita JC, Carvalho-Salles AB, Hackel C.

Prostate Cancer Prostatic Dis. 2002;5(1):28-31. Review.

20.

Cyp17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia.

Tigli H, Yazici H, Dalay N.

Res Commun Mol Pathol Pharmacol. 2003;113-114:307-14.

PMID:
15686129
Items per page

Supplemental Content

Write to the Help Desk